Journals / Türkiye Acil Tıp Dergisi / 2006 / Cilt: 6 - Sayı: 3

Mortal postpartum neuroleptic malignant syndrome

Ölümle sonuçlanan postpartum nöroleptik malign sendrom olgusu

Pages
139–141
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this study, we present a case of postpartum neuroleptic malignant syndrome which ended in the death of the patient, and review the literature.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Neuroleptic malignant syndrome is a serious side effect caused by antipsychotic medications.
📊
Key Findings & Data:The incidence of neuroleptic malignant syndrome with conventional antipsy­chotic agents has been reported to vary from 0.02-2.44%.
💡
Conclusion & Impact:In this study, we present a case of postpartum neuroleptic malignant syndrome which ended in the death of the patient, and review the literature.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Neuroleptic malignant syndrome is a serious side effect caused by antipsychotic medications. Neuroleptic malig­nant syndrome is believed to be triggered by neuroleptic blockade of dopaminergic receptors located in the hypothalamus and basal ganglia. The incidence of neuroleptic malignant syndrome with conventional antipsy­chotic agents has been reported to vary from 0.02-2.44%. Manifestations of this syndrome include severe mus­cle rigidity and high temperature with any of the following symptoms: dysphagia, tremor, incontinence, changes in the level of consciousness, ranging from confusion to coma, mutism, tachycardia, elevated or labile blood pressure, leukocytosis and laboratory evidence of muscle injury characterized by elevated creatinine-phosphoki-nase (CPK). In this study, we present a case of postpartum neuroleptic malignant syndrome which ended in the death of the patient, and review the literature.

Özet

Nöroleptik malign sendrom antipsikotik ilaçların kullanımına bağlı olarak gelişen ciddi bir yan etkidir. Etyopatogenezinde hipotalamus ve bazal gangliyonlarda akut dopaminerjik blokaj olduğu ileri sürülmektedir. Sıklıkla klasik antip­sikotik ilaçlara bağlı olarak %0.02-2.44 gibi değişken oranlarda görüldüğü rapor edilmiştir. Hastalarda musküler rijidite ve yüksek ateş (42°C'ye varabilen) ön plandadır. Disfaji, tremor, idrar ve gaita inkontinansı, konfüzyondan ko­maya kadar uzanan bilinç değişiklikleri, mutizm, taşikardi, oynak kan basıncı, lökositoz ve kas yıkımının bir gösterge­si olarak artmış kreatinin fosfakinaz düzeyleri klinik tablonun diğer unsurlarıdır. Bu yazıda postpartum dönemde nö­roleptik malign sendrom gelişen ve ölümle sonuçlanan bir olguyu, literatür ışığı altında irdelemeyi amaçladık.

🔖

Cite This Article

UYSAL, E., ORAK, M., DOĞAN, H., GÜLOĞLU, C., ÜSTÜNDAĞ, M. (2022). Mortal postpartum neuroleptic malignant syndrome. Türkiye Acil Tıp Dergisi, Cilt: 6 - Sayı: 3, 139–141. https://ajindex.com/articles/626139

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Keck PE Jr, Caroff SN, McElroy SL. Neuroleptic malignant syndrome and malig­ nant hyperthermia: end of a controversy? J Neuropsychiatry Clin Neurosci 1995;7:135-44. 2.John M, Davis MD, Philip G, Janicak, Khan A. Neuroleptic malignant syndrome. In: Dunner DL, editor. Current psychiatric therapy. Philadelphia: Harcourt Broce Jovanich Inc; 1993. p. 170-5. 3.Margetic B, Aukst-Margetic B. Neuroleptic malignant syndrome and clozapine withdrawal at the same time? Prog Neuropsychopharmacol Biol Psychiatry 2005;29:145-7. 4.Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004;65:464-70. 5.American Psychiatric Association. Diagnostic and statistical manual of mental dis­orders. 4th ed. Washington, DC, USA: American Psychiatric Press; 1994. p. 739-42. 6.Harrigan RA, Brady WJ. Antipsychotics. In: Tintinalli JE, Kelen GD, Stapczynski JS, editors. Emergency medicine. 5th ed. New York: McGraw-Hill Companies;2000. p. 1086-7. 7.Gelder M, Gath D, Mayou R, Cowen P. The neuroleptic malignant syndrome. In: Gelder M, Gath D, Mayou R, Cowen P, editors. Oxford texbook of psychiatry. 3rd ed. Oxford University Press; 1996. p. 554-5. 8.Naganuma H, Fujii I. Incidence and risk factors in neuroleptic malignant syn­ drome. Acta Psychiatr Scand 1994;90:424-6. 9.Addonizio G, Susman VL, Roth SD. Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry 1987;22:1004-20. 10.Sachdev P, Mason C, Hadzi-Pavlovic D. Case-control study of neuroleptic malig­ nant syndrome. Am J Psychiatry 1997;154:1156-8. 11.Herken H, Kaya N, Aşkın R, Kucur R. Nöroleptik malign sendrom: 5 Olgu. Klinik Psikiyatri 1998;2:120-4. 12.Fido AA. Postpartum period: a risk factor for neuroleptic malignant syndrome. Ann Clin Psychiatry 1999;11:13-5. 13.Russell CS, Lang C, McCambridge M, Calhoun B. Neuroleptic malignant syn­ drome in pregnancy. Obstet Gynecol 2001;98(5 Pt 2):906-8. 14.Caroff SN. The neuroleptic malignant syndrome. J Clin Psychiatry 1980;41:79-83. 15.Zubenko G, Pope HG Jr. Management of a case of neuroleptic malignant syndrome with bromocriptine. Am J Psychiatry 1983;140:1619-20.